NYMXF (Nymox Pharmaceutical) Total Receivables: $0.03 Mil (As of Dec. 2024)


What is Nymox Pharmaceutical Total Receivables?

Nymox Pharmaceutical NYMXF Total Receivables is $0.03 Mil as of Dec. 2024.

Nymox Pharmaceutical's Total Receivables for the quarter that ended in Dec. 2024 was $0.03 Mil.

Nymox Pharmaceutical Total Receivables Related Terms

Nymox Pharmaceutical Total Receivables Historical Data

* Premium members only.

The historical data trend for Nymox Pharmaceutical's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nymox Pharmaceutical Total Receivables Chart

Nymox Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.01 0.01 0.01 0.03

Nymox Pharmaceutical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Sep24 Dec24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.02 0.03

Nymox Pharmaceutical Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.03 Mil mean?
Nymox Pharmaceutical (NYMXF) has a Total Receivables of $0.03 Mil as of Dec. 2024. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Nymox Pharmaceutical and its competitors.
Is Nymox Pharmaceutical's Total Receivables too high?
Nymox Pharmaceutical's current Total Receivables is $0.03 Mil.
How does Nymox Pharmaceutical's Total Receivables compare to LYRA and RNAZ?
Nymox Pharmaceutical's Total Receivables of $0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Nymox Pharmaceutical and its competitors. Nymox Pharmaceutical's current Total Receivables is $0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nymox Pharmaceutical stock overvalued right now?
Nymox Pharmaceutical (NYMXF) has a current Total Receivables of $0.03 Mil. The current Total Receivables is $0.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Nymox Pharmaceutical (NYMXF), the current Total Receivables is $0.03 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nymox Pharmaceutical Business Description

Address Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and low-grade localized prostate cancer. The company also has an extensive patent portfolio covering its investigational drug as well as other therapeutic and diagnostic indications. It also has U.S. and patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The company operates in one reportable segment, focused on researching and developing products for the aging population.